INHIBIKASE THERAPEUTICS, INC. (IKT) Shareholders’ equity 2020–2024
INHIBIKASE THERAPEUTICS, INC. (IKT) shareholders’ equity at each fiscal year-end, per SEC filings.
$94.9MFY2024 · since FY2020: $9.8M → $94.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | $94.9M | +764.2% |
| FY2023 | $11.0M | -47.8% |
| FY2022 | $21.0M | -45.2% |
| FY2021 | $38.4M | +292.6% |
| FY2020 | $9.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice